Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Successfully completed Protocol PB-06-001 and enrolled in Protocol PB-06-003~* The subject signs an informed consent~Exclusion Criteria:~* Currently taking another investigational drug for any condition.~* Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the subject's compliance with the requirements of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Taliglucerase alfa 30 units/kg (Type: EXPERIMENTAL): Subjects randomized to receive 30 units/kg
- Taliglucerase alfa 60 units/kg (Type: EXPERIMENTAL): Subjects randomized to 60 units/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).